Drug Profile
Research programme: platelet aggregation inhibitors - Evolva Biotech
Latest Information Update: 22 Feb 2010
Price :
$50
*
At a glance
- Originator Evolva Biotech
- Developer Evolva Holding SA
- Class
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Inflammation
Most Recent Events
- 14 Dec 2009 Evolva SA has merged with Arpida to form Evolva Holding SA